(Image credit: This content is subject to copyright.)
In May, the Japanese pharmaceuticals company Takeda made a takeover bid for London-listed Shire (LSE: SHP). Takeda is offering a combination of cash and shares worth $62bn (at Takeda's current share price), which works out at £49 per share. Shire's share price is around £43, so if the bid goes through, Shire's shareholders stand to make a nice return of around 13% assuming Takeda's shares stay at around the same price.
Both firms are global companies, so the deal will need approval from competition authorities around the world, including Japan, Europe and even China. However, because they have focused on different areas, with few overlaps, there are unlikely to be many major issues. Indeed, the deal has already received a green light from the Federal Trade Commission in the US, which suggests it should face few regulatory barriers elsewhere. The EU is expected to approve the deal in the autumn, allowing it to go through at the start of next year.
Perhaps the only real concern is that Shire is too big for Takeda to acquire comfortably without taking on a dangerous level of debt. Indeed, at Takeda's annual meeting in June a group of shareholders tried to sabotage the deal by proposing a resolution that would have required shareholder approval for any major acquisitions. However, in the end the resolution was comfortably defeated.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Even if the deal collapses, Shire still looks like good value. Trading at only 11.3 times forecast earnings for 2018, it is much cheaper than Takeda, which trades at around 20 times forecast earnings, and cheaper than large UK peers such as GlaxoSmithKline (14.4) and AstraZeneca (21.5). Part of the differential can be explained by the fact that the patents on several drugs are set to expire, which will allow companies to launch their own generic versions. Some of its other drugs, most notably treatments for haemophilia and constipation, are also facing competition from alternatives. However, the loss of revenue from this needs to be set against the potential of new drugs emerging from Shire's pipeline.
The fact that Takeda's offer involves both stocks and shares makes things a little complicated, because IG Index will replace your long position in Shire with a long position in Takeda once everything is signed off. However, because Shire looks such good value, I'm going to recommend that you just go long in Shire, and close the position just before the deal is formally completed. In this case we'd go with IG's minimum of £100 per £1, with a stop-loss at £34. With the price currently at £43.25, this means the potential downside is £976.
Trading techniques merger arbitrage
Merger arbitrage betting on takeovers is a popular trading strategy. Usually when a company tries to take over a rival it will have to offer a substantial premium over the share price to convince existing shareholders to sell. As a result, the share price of the target company will usually rise when an offer is made. Conversely, the price of the company doing the buying will often fall. But because there's always a chance that the deal will unravel, the new price of the target will usually still be below the offer price, unless investors expect a higher offer.
There are three ways to trade this situation. If you think the deal won't go ahead, then it makes sense to short the shares of the target, in the expectation that the price will fall back to the original level. If you think the chances of the deal going ahead are better than implied by the markets, you can buy the shares of the company being acquired. However, if the deal involves the acquirer paying partly or wholly in its shares (rather than cash), many merger-arbitrage traders will buy the shares of the target while shorting the shares of the acquirer. By doing this, they eliminate the effect of market movements on their returns, making the outcome solely dependent on whether the deal goes through.
Profits from merger-arbitrage trading are often individually modest, but can add up to decent returns. A 2002 study by Mark Mitchell of Harvard and Todd Pulvino of Northwestern University found that, between 1963 and 1988, a strategy of buying firms that were merger targets, even after the deal had been announced, would have beaten the market by roughly 4% a year.
How my tips havefared
On balance the last fortnight has been pretty good for this column, at least for our long positions. IG Group has gone up to 871p (from 848p), Micron has risen to $56.96 (from $51.48), Redrow is now 541.5p (from 522p) and Wizz Air is £38.13 (from £35.38). The only fly in the ointment is Greene King, which has fallen slightly to 535p. This means that IG Group is making £601, Greene King £304, Micron £260 and Wizz Air £253. Despite the fact that Redrow is losing £285, this means the total paper profits from our long positions are £1,132.
However, our short positions are a different matter. The Financial Stability Board, which aims to harmonise financial regulation across the G20, stated that "crypto-assets do not pose a material risk to global financial stability at this time". Although it did call for more international monitoring, this has been seen as a de facto endorsement of the currency. As a result, the price of bitcoin has surged to $7,523, reducing our paper profits to £926. Meanwhile, despite growing shareholder angst over the actions of founder Elon Musk, Tesla's price has increased slightly to $322.69, putting us £156 in the red.
Overall, we're making £1,899 in paper profits on our open positions, while our closed trades are losing a total of £77. In my previous update, I said that I was considering closing out the positions in Micron and IG Group. Although the positions have been open for a relatively long time, I'm loath to close them while they are still making money. So, I'm going to give them both a stay of execution, though I will raise the stop-loss on IG Group to 825p and Micron to $50. I'm also going to close the bitcoin short position if it rises to above $8,500 (previously $9,000).
Explore More
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
Matthew graduated from the University of Durham in 2004; he then gained an MSc, followed by a PhD at the London School of Economics.
He has previously written for a wide range of publications, including the Guardian and the Economist, and also helped to run a newsletter on terrorism. He has spent time at Lehman Brothers, Citigroup and the consultancy Lombard Street Research.
As senior writer, he writes the shares and politics & economics pages, as well as weekly Blowing It and Great Frauds in History columns He also writes a fortnightly reviews page and trading tips, as well as regular cover stories and multi-page investment focus features.
Review: Eden Roc Cap Cana – fun, sun and golf in the Caribbean
Reeves delays cash ISA reform, but savers are not out of the woods yet
Argentex: opportunities for investors after temporary setback
Three ways to cash in on the digital infrastructure boom
Four more Aim shares to invest in today
Three undervalued mid-cap stocks with attractive prospects
Aviva: One for income investors to tuck away
Three long-term growth stocks to profit from a world that’s getting wealthier
